MPH Health Care AG, a Berlin-headquartered listed investment holding company, has announced its intention to sell up to 927,755 existing shares in M1 Kliniken AG through an accelerated bookbuilding process targeting institutional investors. The shares represent approximately 5 per cent of M1's issued share capital. Assuming full placement, MPH's holding in M1 would fall from approximately 66 per cent to approximately 61 per cent, leaving MPH as majority shareholder. The transaction is designed to increase M1's free float, broaden its institutional shareholder base, and improve trading liquidity in the M1 share on a sustained basis.
Key Points
- MPH Health Care AG (ISIN: DE000A289V03; reference: 0W1Q), listed on the Regulated Unofficial Market in Frankfurt, Dusseldorf, Munich, Stuttgart, and Tradegate
- MPH intends to place up to 927,755 existing M1 Kliniken AG shares, representing approximately 5 per cent of M1's issued share capital, via accelerated bookbuilding
- Trade Date is scheduled for 20 November 2026; Settlement Date is scheduled for 24 November 2026; Cantor is acting as Sole Global Coordinator and Sole Bookrunner
- Investors will be watching for the confirmed placement price and final placement size, expected to be announced on or around 19 November 2026
MPH Sells Existing M1 Kliniken Shares to Broaden Institutional Free Float
The placement is made exclusively from MPH's existing shareholding and does not involve the issuance of new shares in M1 Kliniken AG. The final placement price and the number of shares actually placed will be determined through the bookbuilding process, which commenced immediately after publication of the announcement following the close of Xetra trading on 19 November 2026. The order book may be closed at short notice, the announcement states. The shares offered carry full dividend entitlement for the financial year 2026, which may be a consideration for participating institutional investors.
MPH Retains Majority Control With Approximately 11.4 Million M1 Shares After Full Placement
Assuming the placement is completed in full, MPH would continue to hold approximately 11.4 million shares in M1 Kliniken AG, maintaining its position as majority shareholder with a stake of approximately 61 per cent. CEO Patrick Brenske stated in the announcement that the placement aims to broaden the institutional shareholder base and enhance the tradability of the M1 share, while MPH's continued majority holding underlines its long-term commitment to M1 and to the further development of the company. MPH has also entered into a three-month lock-up undertaking on its remaining M1 shares, subject to customary exceptions.
M1 Kliniken AG Operates 59 Clinics Across Ten Countries Under M1 Med Beauty Brand
M1 Kliniken AG is described in the announcement as the central holding within MPH's portfolio. The company operates 59 clinics across ten countries under the M1 Med Beauty brand, positioning it as a multi-market aesthetic medicine operator. MPH itself is a listed investment holding company focused on the development and long-term value creation of equity investments, particularly within growth segments of the healthcare market. The scale of M1's clinic network across multiple jurisdictions is a key asset underpinning MPH's portfolio concentration in the healthcare sector.
Cantor Coordinates Bookbuilding With Settlement Scheduled for 24 November 2026
Cantor is acting as Sole Global Coordinator and Sole Bookrunner for the transaction. The Trade Date is scheduled for 20 November 2026, with Settlement Date set for 24 November 2026. Results of the placement are expected to be announced on or around 19 November 2026. The placement is restricted to qualified institutional investors and is not available to retail investors in the United Kingdom or European Economic Area. Investors may be watching for the confirmed pricing outcome and any subsequent update to MPH's disclosed shareholding position in M1 Kliniken AG following settlement.




Please wait processing your request...